In recent years,the incidence of type 2 diabetes mellitus(T2DM)caused by obesity in China has been increasing continuously,which has become a risk factor for the onset of T2DM and seriously affects the quality of life...In recent years,the incidence of type 2 diabetes mellitus(T2DM)caused by obesity in China has been increasing continuously,which has become a risk factor for the onset of T2DM and seriously affects the quality of life of patients.The conventional treatment methods include weight loss and regulating the body’s metabolism.Semaglutide,as a glucagon-like peptide-1 receptor agonist(GLP-1RA),mainly reduces patients’appetite,decreases their craving for high-fat and high-sugar foods,regulates hypothalamic feeding behavior,inhibits gastric emptying and gastrointestinal motility,and ultimately leads to weight loss.Metformin mainly acts on extra-islet tissues,increasing glucose utilization,reducing glucose production,and ultimately lowering blood glucose levels.Based on this,this article reviews relevant literature on authoritative websites such as CNKI and Wanfang,organizes the data,and analyzes the research progress of semaglutide combined with metformin in the treatment of obese T2DM.The aim is to bring more treatment options for obese T2DM and promote better prognosis for patients.展开更多
文摘In recent years,the incidence of type 2 diabetes mellitus(T2DM)caused by obesity in China has been increasing continuously,which has become a risk factor for the onset of T2DM and seriously affects the quality of life of patients.The conventional treatment methods include weight loss and regulating the body’s metabolism.Semaglutide,as a glucagon-like peptide-1 receptor agonist(GLP-1RA),mainly reduces patients’appetite,decreases their craving for high-fat and high-sugar foods,regulates hypothalamic feeding behavior,inhibits gastric emptying and gastrointestinal motility,and ultimately leads to weight loss.Metformin mainly acts on extra-islet tissues,increasing glucose utilization,reducing glucose production,and ultimately lowering blood glucose levels.Based on this,this article reviews relevant literature on authoritative websites such as CNKI and Wanfang,organizes the data,and analyzes the research progress of semaglutide combined with metformin in the treatment of obese T2DM.The aim is to bring more treatment options for obese T2DM and promote better prognosis for patients.
